The rescue of F508del-CFTR by elexacaftor/tezacaftor/ivacaftor (Trikafta) in human airway epithelial cells is underestimated due to the presence of ivacaftor

Autor: Thomas Carrez, Arnaud Billet, Christelle Coraux, Manuella Lévêque, Edouard Sage, Sandra Mirval, Frédéric Becq, Anne Cantereau

Publikováno v: European Respiratory Journal
European Respiratory Journal, European Respiratory Society, 2021, pp.2100671. ⟨10.1183/13993003.00671-2021⟩

Trikafta, currently the leading therapeutic in cystic fibrosis (CF), has demonstrated a real clinical benefit. This treatment is the triple combination therapy of two folding correctors elexacaftor/tezacaftor (VX445/VX661) plus the gating potentiator

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d0dffa4bfabe10cad5b1ab13d46687c3
https://hal.univ-reims.fr/hal-03325595